兔头妈妈锚定儿童洗护科研创新 获评浙江省专精特新中小企业再攀高峰

Core Viewpoint - The recognition of the children's age-specific care brand "Rabbit Head Mama" as a provincial "specialized, refined, and innovative" small and medium-sized enterprise highlights the company's commitment to independent research and innovation, particularly in the development of the self-researched ingredient "Ola Flu" and related foundational research, marking a significant advancement in the children's care segment [1][3][7]. Group 1: Company Overview - Rabbit Head Mama was established in 2018 and focuses on children's oral and skin health, guided by the principle of "love and science" [3]. - The company has invested over 100 million in establishing a research and development center in Hangzhou, which includes 10 specialized laboratories aligned with CNAS standards [3]. - Rabbit Head Mama has accumulated nearly 40 proprietary patents and has been recognized as a national high-tech enterprise and a high-tech research and development center in Hangzhou [3]. Group 2: Technological Innovations - The company has gained attention for its breakthrough in the domestic research of "Ola Flu," which has been reported by major media outlets for overcoming a 60-year technology monopoly [6][7]. - In July 2024, Rabbit Head Mama successfully synthesized the anti-cavity ingredient "Ola Flu" in the laboratory, completing research on detection methods, component characterization, performance evaluation, safety assessment, and preparation methods [6][7]. - The new generation of "Ola Flu" toothpaste launched earlier this year demonstrates significant efficacy: 12-hour long-lasting anti-cavity protection, a 42.96% increase in enamel hardness over 28 days, a 99.9% antibacterial rate, and a 65.8% acid resistance [7]. Group 3: Market Impact and Future Prospects - The recognition as a "specialized, refined, and innovative" enterprise not only affirms the company's technological innovations but also encourages domestic brands to increase research and development investments [6][7]. - The successful development of the patented small molecule bionic fetal fat peptide in the children's skincare sector enhances the company's ability to address common skin issues in children, showing improvements in anti-sensitivity and inflammation reduction [7].